Akebia Therapeutics (AKBA) Misses Q4 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.10), $0.03 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $46.49 million versus the consensus estimate of $49.57 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Armata gets $2.5M more in DoD funding for bacteriophage drug
• Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand